Patents Assigned to Abcentra, LLC
  • Methods for treatment of psoriasis with an anti-oxLDL antibody
    Patent number: 12616749
    Abstract: Compositions and methods for treating a subject with psoriasis are provided, including an inhibitor of oxidized low density lipoprotein (LDL), malondialdehyde-modified epitope in LDL or native LDL for administration. Exemplary inhibitors of oxidized or malondialdehyde-modified LDL include orticumab, a variant antibody or peptides capable of binding oxidized or malondialdehyde-modified LDL, which results in improvement in conditions of psoriasis even in patients that are refractory to ultraviolet A/B therapy and topical steroids.
    Type: Grant
    Filed: June 21, 2024
    Date of Patent: May 5, 2026
    Assignee: Abcentra, LLC
    Inventors: Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
  • Methods for treating cancer with an anti-apo B100 antibody
    Patent number: 12570731
    Abstract: The present invention provides compositions and methods for treating cancer in a subject by administering to the subject an antibody or fragment thereof that binds to oxidized LDL. In some embodiments, the compositions and methods may reduce the size of the tumor, reduce macrophage infiltration, and/or inhibit metastasis.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: March 10, 2026
    Assignee: Abcentra, LLC
    Inventors: Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
  • Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody
    Patent number: 12458694
    Abstract: Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.
    Type: Grant
    Filed: May 22, 2023
    Date of Patent: November 4, 2025
    Assignee: Abcentra, LLC
    Inventors: Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
  • Methods for treatment of psoriasis with an anti-Apo B100 antibody
    Patent number: 12016921
    Abstract: Compositions and methods for treating a subject with psoriasis are provided, including an inhibitor of oxidized low density lipoprotein (LDL), malondialdehyde-modified epitope in LDL or native LDL for administration. Exemplary inhibitors of oxidized or malondialdehyde-modified LDL include orticumab, a variant antibody or peptides capable of binding oxidized or malondialdehyde-modified LDL, which results in improvement in conditions of psoriasis even in patients that are refractory to ultraviolet A/B therapy and topical steroids.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: June 25, 2024
    Assignee: Abcentra, LLC
    Inventors: Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
  • Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
    Patent number: 11690912
    Abstract: Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 4, 2023
    Assignee: Abcentra, LLC
    Inventors: Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
  • Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
    Patent number: 10858422
    Abstract: Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: December 8, 2020
    Assignee: Abcentra, LLC
    Inventors: Jan Nilsson, Ryan Benjamin Abbott, Bertrand C. Liang, Christopher John Farina, Stacey Ruiz
  • Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
    Patent number: 10434141
    Abstract: Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: October 8, 2019
    Assignee: Abcentra, LLC
    Inventors: Jan Nilsson, Ryan Benjamin Abbott
  • METHODS FOR DIAGNOSING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSUS WITH AN ANTI-APOLIPOPROTEIN B ANTIBODY
    Publication number: 20190284268
    Abstract: Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.
    Type: Application
    Filed: May 31, 2019
    Publication date: September 19, 2019
    Applicant: Abcentra, LLC
    Inventors: Jan Nilsson, Ryan Benjamin Abbott, Bertrand C. Liang, Christopher John Farina, Stacey Ruiz